liver cancer

Golfer devastated after just barely missing a putt

Pharma

Merck, Eisai call it quits on Keytruda-Lenvima in liver cancer type

After a prior primary endpoint win raised hopes for the combo's potential in non-metastatic liver cancer, a survival miss brings the study to a close.

Zoey Becker Oct 29, 2025 11:32am

BMS follows Roche, AstraZeneca into first-line liver cancer

Apr 11, 2025 1:53pm

FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again

Mar 21, 2025 3:25pm

Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype

Sep 14, 2024 10:30am

UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 combo

Jul 12, 2024 12:08am

Junshi, Coherus move Loqtorzi closer to another approval

Jun 12, 2024 11:45am